<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE316nnn/GSE316025/</Other></files><type>primary</type></body><statusCodeValue>200</statusCodeValue><statusCode>OK</statusCode></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316025</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Feeder-free generation of CD4 single-positive helper T cells from human iPSCs via stage-specific modulation of Notch and TCR Signaling</name><description>Induced pluripotent stem cell (iPSC)-derived T cells (iPS-T cells) represent a promising platform for adoptive immunotherapy, offering an unlimited source of T cells amenable to gene editing and rigorous quality control. While feeder-free in vitro redifferentiation systems have been successfully developed for CD8+ cytotoxic T cells, the generation of CD4+ helper T cells under similar conditions has remained elusive—despite their essential role in sustaining long-term immune responses. In this study, we established a feeder-free culture system for the generation of CD4 single-positive (SP) helper T cells from iPSCs, under conditions that exclude TCR signaling, which otherwise biases differentiation toward the cytotoxic lineage. By precisely modulating Notch and integrin signaling in a stage-specific manner, we induced the differentiation of CD4 SP iPS-T cells expressing key helper-associated molecules, including CD40L and ThPOK, capable of promoting dendritic cell maturation. Notably, these cells also acquired cytotoxic activity upon repeated expansion while retaining robust proliferative capacity. Our findings provide a foundation for the scalable and consistent production of both CD4 SP helper and killer T cells from pluripotent stem cells, advancing the potential of iPSC-based immunotherapies.</description><dates><publication>2026/06/23</publication></dates><accession>GSE316025</accession><cross_references><GSM>GSM9443498</GSM><GSM>GSM9443487</GSM><GSM>GSM9443488</GSM><GSM>GSM9443499</GSM><GSM>GSM9443489</GSM><GSM>GSM9443500</GSM><GSM>GSM9443483</GSM><GSM>GSM9443494</GSM><GSM>GSM9443495</GSM><GSM>GSM9443484</GSM><GSM>GSM9443485</GSM><GSM>GSM9443496</GSM><GSM>GSM9443486</GSM><GSM>GSM9443497</GSM><GSM>GSM9443490</GSM><GSM>GSM9443480</GSM><GSM>GSM9443491</GSM><GSM>GSM9443492</GSM><GSM>GSM9443481</GSM><GSM>GSM9443482</GSM><GSM>GSM9443493</GSM><GPL>28038</GPL><GSE>316025</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>